EGFR-mutated NSCLC is typically sensitive to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib, osimertinib, Lazertinib and almonertinib, which are small-molecule inhibitors that target the ATP-binding site of the EGFR tyrosine kinase domain (20–23). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.